We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cyprotex | CRX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 160.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 160.50 | 160.50 |
| Top Posts |
|---|
Posted at 26/10/2016 08:08 by rrb Gutted. Who the hell has advised the board to accept such a low offer? The premium should have been at least 100%. Evotec managed to buy a growing company at just over 3 x sales.Another sad day for the private investor. I'm sure the board will be well looked-after. |
Posted at 21/10/2016 22:23 by p1nkfish I disagree. They are just capitalist investors like the rest of us. You can partially take part in TRIDENT III if you take a holding in NAS. There's nothing to stop you. If you can't beat them, join them. |
Posted at 12/10/2016 15:11 by chadders Trading update eagerly anticipated. More surprises on the upside and this should continue its upward trajectory. Just a flavour from the interims below,Ian Johnson, Chairman of Cyprotex PLC, said: "I am delighted to report that the progress made in 2015 has continued into 2016 and, as previously flagged to the market, we are substantially ahead of our expectations. The growth of the business is global and from an increasingly wide range of industries and sectors. Investment in all sites, which commenced in 2014, continues and is delivering high quality new services which contributed to the increase in revenue in H1 2016. Watertown and both UK sites have grown revenues and consequently operational profitability. The Kalamazoo site has received considerable investment to launch a suite of GLP genotoxicity services which we expect will drive revenue growth for the site in the second half of the year. Of note is the collaboration with Cytocentrics announced in February 2016 where we are developing a full range of ion channel services to meet the expected regulatory changes in cardiac safety testing as a consequence of the CiPA initiative. The second half has started well and the Board looks forward to the remainder of the year with continued confidence." Methinks the Kalamazoo investment will have a major impact. I'm an investor so DYOR |
Posted at 06/4/2016 08:28 by buywell2 POST REMOVED |
Posted at 03/4/2016 12:20 by p1nkfish take a look at INS.worth investigation on a 3-5 yr view. am in sbs and odx as investments for 3-5 view. odx has sneller as investor also, like crx. |
Posted at 31/3/2016 17:55 by buywell3 That is what we have a BOD for ... to give us an outlookThe Finals should give some direction I like and hope North is what we get .... and all Cyprotex Investors will be in the pink. The recent surge in work leading to the raised turnover/profits now expected for 2015, (finals in a fortnight I think ), seems to indicate the outlook is both rosy and north for 2016. |
Posted at 27/3/2016 10:41 by buywell2 ........... The Cyprotex Group and The Source BioScience Group..........Both of these companies state that they are committed to ''increasing value for shareholders'' page 18 Commitment to increase shareholder value Both of these companies operate in the Pharma Biotech sector, both have considerable presence in the UK and also in the USA (where SBS wants to become the leading DNA Sequencing provider : see their finals extract to follow) DNA Sequencing and Genomic Services ''The DNA Sequencing and Genomic Services business provides ultra-fast DNA sequencing services delivered by the Group's international network of laboratories and distributors to academic research groups, biotechnology and pharmaceutical companies. Source BioScience's ambition is to become the leading commercial provider of DNA sequencing in the UK and the USA. The Group's ultra-fast service, with data delivery times of less than ten hours, and international laboratory network continues to power the growth of this business. Over 1 million customer samples for DNA sequencing were analysed during the year, an increase of 15% compared with the prior year. In 2015 the DNA sequencing service was launched from the Group's facilities in Atlanta for customers in the south east of the USA.'' Both of these companies state that they are committed to ''increasing value for shareholders'' From last weeks SouceBioScience Finals results Outlook ''We believe that the Group has a very strong business model and opportunities for further growth are apparent across the Laboratory Services and Products divisions. The Board's strategy is to expand the service and product offering, enabling greater market penetration, with the objective of delivering increasing value for shareholders. The aim is to achieve this through continued organic growth from the enlarged infrastructure in addition to further, carefully selected acquisitions when the opportunities arise, building on the strong foundations now established in the business.'' The top two Institutions of The SourceBioScience Group are : Harwood Capital ............... 29.4% Henderson Global Investors .... 5.0% (in the form of Alphagen Volantis notes) The same two Institutions own shares in The Source BioScience Group Harwood Capital ............... 23.5% Henderson Global Investors .... 20.0% I put it to the above companies and Institutional funds that to deliver increased shareholder value for both companies the following should be undertaken . Cyprotex and Source BioScience should enter into a 50/50 strategic partnering deal. The objective would be increase turnover in both companies. 1. By utilizing cross selling each others services to each others clients. 2. By the utilization/expansio Remember SBS offer a ultra fast service that is 10 hours for delivery of data ... thus further USA Geographical locations are going to be needed. 3. By the provision of a cold storage facility in both Labs Number 2 could be undertaken on a 50/50% basis for an agreed period , say 3 to 5 years Number 3. could follow on if 1. and 2. proved to be fruitful Cyprotex has recently created a new BioSciences Division , it is growing and offers complementary assays in areas where SourceBioScience has none. Cyprotex has a massive range of ADME Tox assays where SourceBioScience has next to none having all but exited that growth market some 3 years ago. I believe that a shred 50/50% deal would increase the shareholder value in the following ways a) On the day/s of the announcements the share prices of both companies should rise by around 10% ( this makes the raising of further funds for new acquisitions better for existing shareholders - less dilutive affect ) b) It is not unrealistic to assume the turnover of both companies on a shared basis - equal input/work/selling - would rise 5% in the first year due to such a deal , and then grow another 5% over the next 2 further years. If number 3. above was then implemented in a similar fashion(after year.3 , with the creation of diagnostic testing services from USA Cyprotex Labs , then another 5% to 10% could be added over the following 3 years. All of the above and more could be written in as part of the strategic partnership deal - investors would like it as it makes sense and increases market reach/penetration for both at a minimum cost with an agreed split of monies 50/50%. It's a win/win ..... please make it happen |
Posted at 10/3/2016 22:22 by buywell2 For a small cap company Cyprotex are getting themselves organised to meet the changing environment that is coming about due to regulatory changes occurring and in the pipelineThis latest initiative should help expand Cyprotex services further into the Chemical and Cosmetics industries , building upon the IP gained by the USA CeeTox acquisition. One might go so far as the are punching well above their weight .... and mixing it with the big boys. The modernization of the company's offerings in terms of human cellular based assays and services, together with the shift in focus to industries other than the traditional Pharma ..... seems now to be paying off. Results for 2015 , to be published within days , should also I hope contain guidance as to aspirations for an increase in turnover for 2016. I hope for a 15% increase in turnover .... and of course , more than that in profits. Cyprotex PLC Launch of New Chemical and Cosmetics Testing Guide 09/03/2016 7:01am RNS Launch of New Chemical and Cosmetics Testing Guide Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announces the launch of their new 'Chemical and Cosmetics Testing' guide. The guide is focused in the field of chemical (including pesticides and industrial chemicals) and cosmetics testing and covers an overview of the US and EU legislation/guidance Cyprotex has considerable expertise in this field since its acquisition of the business and assets of CeeTox, Inc in January 2014. This facility, which now forms part of the subsidiary Cyprotex US, LLC, is based in Kalamazoo in Michigan in the USA. It specialises in chemical and cosmetic testing approaches and can perform these studies under Good Laboratory Practice (GLP), which can be a requirement when submitting the data to the regulatory authorities. Sharing of knowledge and experience is a key part of Cyprotex's social responsibility policy. The new 'Chemical and Cosmetics Testing' guide complements Cyprotex's existing 'Everything you need to know about ADME', 'DDI Regulatory Guidance' and 'Mechanisms of Drug-Induced Toxicity' guides. The guides, which are extremely popular with customers, academic institutions and investors alike, provide a valuable resource for scientists in a range of disciplines who want to have an up-to-date overview of the current legislation and testing methods. Anthony Baxter PhD, Chief Executive Officer of Cyprotex, commented: 'The chemical and cosmetics industries are undergoing considerable change. This has been led by the European Cosmetics Directive which, in 2013, enforced a complete ban on animal testing for finished cosmetic products and ingredients. The introduction of REACH (an EU Regulation concerning the risks from chemicals) in 2007 has also meant that alternative non-animal methods are being encouraged to reduce the impact on animal testing requirements. Through our experience in in vitro testing approaches, we can assist our customers in meeting these changes in legislation and help to reduce the burden on animal testing.' |
Posted at 19/11/2015 22:57 by buywell3 buywell2 has mentioned 30M several times in recent yearsAnother decent contract win might do the trick ... perhaps a government one ? Is Cyprotex plc a Buy? The Stock Gapped Up Today November 16, 2015 · The stock of Cyprotex plc (LON:CRX) gapped up by GBX 0.747 today and has GBX 229.38 target or 176.00% above today’s GBX 83.11 share price. The 6 months technical chart setup indicates low risk for the GBX 18.39 million company. The gap was reported on Nov, 17 by Barchart.com. If the GBX 229.38 price target is reached, the company will be worth GBX 32.37M more. Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 3.89% or GBX 3.11 on November 16, hitting GBX 83.11. About 72,681 shares traded hands or 320.41% up from the average. Cyprotex plc (LON:CRX) has risen 50.00% since April 20, 2015 and is uptrending. It has outperformed by 53.47% the S&P500. After Today’s Huge Increase, Is Cyprotex plc’s Near-Term Analysis Positive? November 17, 2015 The stock of Cyprotex plc (LON:CRX) is a huge mover today! The stock is down 1.06% or GBX 0.89 after the news, hitting GBX 83.11 per share. Cyprotex plc (LON:CRX) has risen 50.00% since April 20, 2015 and is uptrending. It has outperformed by 52.54% the S&P500. The move comes after 9 months positive chart setup for the GBX 17.97M company. It was reported on Nov, 17 by Barchart.com. We have GBX 159.57 PT which if reached, will make LON:CRX worth GBX 16.53M more. |
Posted at 21/8/2014 08:08 by buywell2 Which 'boys' are you referring to ?My question is ? What will a price rise on the CSX do to the UK traded shares ? What could happen is another company or other institution taking a big chunk of these and UK shareholders probably not knowing who they are or how many they purchased. pink1 ''The UK Inland Revenue in March of 2004 designated the CSX a "recognised stock exchange" under Section 841 of the Income and Corporation Taxes Act 1988. '' 1. INTRODUCTION The Cayman Islands Stock Exchange (the "CSX") commenced operations in July 1997 and currently lists more than 1,700 issues with aggregate capitalisation in excess of US$168bn. The CSX has developed sophisticated listing rules tailored to meet the needs of issuers with the latest structures and products. Securities listed on the CSX include investment funds (which includes both openended and closeended funds), specialist debt, eurobonds, domestic and international equities and derivative warrants. In addition, Segregated Portfolio Companies (or SPC's, as they are referred to in the industry) with protected cells or portfolios are also listed on the CSX. Investment funds represent some 62% of all listings and this memorandum highlights the principal features that have attracted so many investment operators to the CSX. 2. CSX RECOGNITION The CSX was the first offshore stock exchange to be granted approved registered organisation status by the London Stock Exchange (the "LSE") in July 1999. This approved status denotes that the CSX is able to demonstrate that its regime for listed securities meets all the detailed criteria for inclusion in the list of LSE registered organisations. Listed securities on an LSE registered organisation exchange are eligible for trading on the LSE's international equity market. In 2001, the CSX became the first offshore exchange to join the Intermarket Surveillance Group, which is an international group of twentythree stock exchanges from five countries committed to the coordination of confidential market information sharing for regulatory purposes and regulatory efforts across the markets represented. In 2003, the International Organization of Securities Commissions ("IOSCO") voted to approve the CSX as an affiliate member. IOSCO is the leading international group of securities market regulators. Through mutual assistance IOSCO promotes the integrity of the markets by a rigorous application of its standards and by enforcement against offences. Its current membership comprises regulatory bodies from 91 countries that have daytoday responsibility for securities regulation and the administration of securities laws. The UK Inland Revenue in March of 2004 designated the CSX a "recognised stock exchange" under Section 841 of the Income and Corporation Taxes Act 1988. This designation is an important development for investment funds. Under UK regulations shares in companies listed on the CSX are now permitted investments for self invested personal pension schemes. The UK Inland Revenue has also confirmed that all occupational pension schemes are now entitled to invest in shares listed on a recognised stock exchange. 3. THE BENEFITS OF LISTING A listing on the CSX brings with it a multitude of benefits to the listed security. One such benefit is the increased prestige and profile of the security. A listing on a well regulated and recognised stock exchange, such as the CSX, provides a valuable marketing tool for the promoters. Because certain types of investors may only invest in listed, rather than unlisted securities, a listing enhances the marketability of the security and gives it access to a wider investor base. Many investors mark their investments to market and require that these investments have publicly quoted stock exchange prices. Once a security is listed on the CSX, price and other information will be publicly available, ensuring transparency for investors. This guarantees visibility for the issuers at all times. Information such as the net asset values and any relevant announcements made relating to a listed security are publicly available on the CSX website and dedicated Bloomberg facilities. 4. CSX ADVANTAGES The CSX listing requirements, with their emphasis on disclosure of relevant information, are appropriate for the sophisticated investors who purchase and trade in these security products. English, being the common language of the world of international finance, is the language used for all listing documents. A CSX listing offers the promoters of investment securities of all descriptions an effective platform for attracting investment whilst adding credibility and prestige to their securities. The CSX Listing Rules have been developed with emphasis on full and proper disclosure to potential investors as a fundamental starting point for regulation and have been specifically designed to be clear and easy to understand. The CSX staff has experience in listing many types of investment vehicles including hedge funds, feeder funds, umbrella funds and funds specialising in particular products including property, venture capital and emerging markets. The CSX listing team has extensive knowledge of the investment securities sector and provides a flexible and efficient service at costs which are competitive with, or more attractive than, those of other listing centres. 5. COMPARISON OF THE CSX TO OTHER EXCHANGES Unlike other listing centres, there are no requirements in the CSX's listing rules for a local listing agent to be appointed in connection with an application to list specialist debt securities. The lead manager or the issuer's legal advisors may deal directly with the CSX's listing department. This approach helps to reduce costs and improve efficiency. In addition, again unlike other listing centres, the CSX is not bound by the European Union Listing Directives. This permits the CSX be more flexible in its approach to listing securities. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
